Which of the following statements is/are correct regarding the CDSCO's 2025 approval for Metformin Sustained Release (SR)?
1. It mandates Metformin SR as the only allowed first-line treatment over insulin for gestational diabetes mellitus.
2. The approval was based on recommendations by the Endocrinology and Metabolism Subject Expert Committee (SEC).

Question

Accepted Answer

B. 2 only — Statement 1 is incorrect because Metformin SR is approved as an 'addition or an alternative to insulin based on treating physician discretion', not as a mandatory sole replacement. Statement 2 is correct, as the SEC formally recommended the prescribing label update to the CDSCO.

CDSCO Approves Metformin SR for Pregnancy

Maiden Test of Pinaka Long-Range Guided Rocket